Vitamin B6: pyridoxine hydrochloride,
does it really help with Lower mean pain NRS in painful diabetic distal symmetric polyneuropathy?
research showsWithin the recorded search and selection scope at the cutoff, no directly eligible between-group NRS result was verified. ? denotes the state of currently verified direct evidence, not no effect, a 0 score or worldwide absence of studies. [S01][S02][S03][S04]
ads claimLabels such as B-complex, nerve vitamin or active form do not establish pain relief from this intervention. Improvement with a combination is not a pyridoxine-alone effect. [S05][S13]
Four separate assessment dimensions
| Effect direction and size | Within the recorded search and selection scope at the cutoff, no directly eligible between-group NRS result was verified. ? denotes the state of currently verified direct evidence, not no effect, a 0 score or worldwide absence of studies. [S01][S02][S03][S04] |
|---|---|
| Evidence certainty | Unverified directly eligible NRS results yield ?; existence of human trials is not denied. |
| Applicability | Adults with painful diabetic distal symmetric polyneuropathy; distinct from treatment solely to correct B6 deficiency |
| Safety | Warning |
Uses the unchanged calculator gate0 and a null score. The seven axes are not an additive points scale. Unevaluated axes and strengths are null, not zero. The user-defined current-value interpretation is explicitly scoped to unverified eligible human results.
Useful facts when choosing a product
- This question is limited to mean pain NRS in adults with painful diabetic distal symmetric polyneuropathy. It compares oral pyridoxine hydrochloride alone with placebo on comparable background care.
- The original describes pharmacy random assignment, double blinding, matching placebo tablets, instructions to maintain diet and medication, and supply of active/placebo tablets by Hoffman LaRoche. Adherence, exact analgesics, rescue therapy, full funding and author conflicts were not adequately verified. [S02]
Chamgap Semantic Classification Code
Permanent code issued
S.pyridoxine-hydrochloride.oral.diabetic-peripheral-neuropathy-pain.reduce.placeboSubstances and nutrients > Pyridoxine hydrochloride monotherapy > Oral > Pain in painful diabetic peripheral neuropathy > Reduction claim > Placebo
Bound to the ChatGPT-fixed mean-pain-NRS claim in adults with painful diabetic distal symmetric polyneuropathy. Eligible dose, duration, instrument, timepoint and between-group effect remain unresolved. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Vitamin B6: pyridoxine hydrochloride alone |
| Source or part used | Not verified: manufacturing origin and raw-material source |
| Formulation or processing | Oral single-ingredient supplementation question. Eligible NRS study form unverified; adjacent Levin study used tablets; release, purity and batch unverified |
| Route | Oral |
| Dose | Not verified for an eligible mean-NRS comparison. Adjacent 50 mg every 8 hours is not an efficacy-established regimen |
| Duration | Eligible NRS time unverified. Ordinal symptoms from the adjacent 4-month trial not converted to NRS |
| Population | Adults with painful diabetic distal symmetric polyneuropathy; distinct from treatment solely to correct B6 deficiency |
| Effect or condition | Reduction of neuropathic pain intensity |
| Primary endpoint | Between-group difference in mean pain NRS change. Preferred question range 0–10; eligible instrument, time and denominator unverified. VAS separate |
| Comparator | Question of placebo on comparable background care; eligible trial placebo composition, analgesics and rescue therapy unverified |
| Duplicate-detection key | pyridoxine-hydrochloride|oral|dose-not-verified|painful-diabetic-dspn|mean-pain-nrs|duration-not-verified|placebo-on-comparable-background-care |
What the research actually shows
The Levin trial involved 18 symptomatic diabetes patients and used pyridoxine hydrochloride 50 mg 3 times daily for 4 months. The scheduled total of 150 mg/day is calculated, not a dosing recommendation. [S01][S02]
Substantial neuropathic symptom relief was reported by 6/9 in the B6 group and 4/9 with placebo. This is a response category covering pain or paresthesia, not a mean NRS/VAS difference or a 50% pain-response rate. [S01][S02]
The paper used its own categories: worse −1, unchanged 0, slight improvement +1, substantial improvement +2. These were neither relabeled as validated NRS nor converted to an equal-interval continuous scale. [S02]
The original describes pharmacy random assignment, double blinding, matching placebo tablets, instructions to maintain diet and medication, and supply of active/placebo tablets by Hoffman LaRoche. Adherence, exact analgesics, rescue therapy, full funding and author conflicts were not adequately verified. [S02]
The older McCann and Cohen monotherapy candidates were verified only bibliographically, without original numerical results. Failed access was not counted as a null result; the presence of a directly eligible NRS result remains unverified. [S03][S04]
Why this is classified as ?
The original calculator gate 0 yields ? with score null. Clinical claim B and patient-reported endpoint P classify the question; the other five axes and the strength count are unscored null at this gate. The assessment profile explicitly states that human B6 studies do exist.
Counterpoint. The older McCann and Cohen monotherapy candidates were verified only bibliographically, without original numerical results. Failed access was not counted as a null result; the presence of a directly eligible NRS result remains unverified. [S03][S04] The PLP/folate/B12 combination Metanx, an uncontrolled foot-pain report, and a metabolic/oxidative-stress study were recorded separately. Favorable descriptions were retained but not attributed to a B6-alone NRS analgesic effect. [S05][S06][S07] Baseline, change and endpoint mean pain values, between-group difference, CI, P value, analysis denominator and an applicable MCID are unverified. Nerve conduction, PLP, fasting glucose and general symptom relief were not used to fill these gaps. [S01][S02][S03][S04]
Rejudgment record. No directly eligible between-group mean pain NRS result verified for the fixed question. Adjacent human studies exist. — Original calculator gate0 with endpoint-scoped current-value interpretation; unscored axes remain null.
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests Case application: Pain intensity is a patient-reported treatment goal; this classifies the question, not verified results |
Stored derived and displayed grades match; this is not a current recalculation or validity check (?).
Review performed and remaining limitations
The older McCann and Cohen monotherapy candidates were verified only bibliographically, without original numerical results. Failed access was not counted as a null result; the presence of a directly eligible NRS result remains unverified. [S03][S04] Baseline, change and endpoint mean pain values, between-group difference, CI, P value, analysis denominator and an applicable MCID are unverified. Nerve conduction, PLP, fasting glucose and general symptom relief were not used to fill these gaps. [S01][S02][S03][S04] Exact origin, eligible formulation, dose, duration, diagnosis criteria, background analgesics, rescue therapy, adherence, funding, conflicts and long-term safety are also unverified. Unverified does not mean absent from the study.
Preliminary RoB 2-informed review — not a complete formal assessment
| Randomization | Pharmacy randomization and blinding verified for adjacent Levin study; detailed concealment unverified. |
|---|---|
| Deviations from assigned interventions | Diet/medication maintenance instructions; adherence, analgesic and rescue details unverified. |
| Missing outcome data | Completion of all visits and endpoint missingness unverified; categorical-response denominators not imputed as NRS analysis counts. |
| Outcome measurement | Arbitrary ordinal scale is not validated mean NRS and is excluded from the current endpoint. |
| Selection of the reported result | Prospective protocol, multiplicity and selective reporting unverified. Uncertainty is not labeled as a proven defect. |
Reasons for the certainty judgment — not formal GRADE
| Risk of bias | Candidate designs recorded separately; no duplicate deduction after gate0. |
|---|---|
| Inconsistency | No inconsistency score assembled from ineligible scales and unverified results. |
| Indirectness | Combinations, mechanisms, general symptoms, nerve conduction and other neuropathies are separated. |
| Imprecision | Eligible between-group effect, CI and MCID unverified; no reconstruction. |
| Publication bias | Registry access limitations preclude assurance of complete unpublished-study coverage. |
Search scope and limitations. Executed searches, access logs and selection reasons retained in search_log.json, url_access_log.json and selection_log.json.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Levin et al. 1981 | Pharmacy-randomized double-blind parallel placebo control; detailed concealment unverified | 18 total; symptom-category denominators 9/9. Eligible NRS analysis denominator unverified | Active/placebo tablets supplied by Hoffman LaRoche; full funding, employment and patents unverified | Arbitrary symptom-change categories −1/0/+1/+2; not mean NRS | Substantial pain-or-paresthesia relief 6/9 versus 4/9. Formal mean-NRS effect and CI unverified | Not used for direct grading of the fixed endpoint: Arbitrary symptom-change categories covering pain or paresthesia, not a validated mean pain NRS result; exact painful DSPN enrollment criterion unverified. |
| McCann et al. 1983 | Double-blind controlled per title; details unverified | Not verified | Not verified | Pain instrument, time and hierarchy unverified | Metadata only; failed access not treated as a null effect | Not used for direct grading of the fixed endpoint: Primary metadata, no abstract; primary pain instrument, full results, dose/schedule and denominators not obtained. Review-level quantities not treated as verified. |
| Cohen et al. 1984 | Clinical trial indexed; allocation/control details unverified | Not verified | Not verified | Pain instrument, time and hierarchy unverified | Metadata only; direct pain results unverified | Not used for direct grading of the fixed endpoint: Primary metadata without abstract; publisher403. No negative NRS effect inferred. |
| Metanx randomized trial | Multicenter randomized double-blind placebo-controlled combination trial | Sample size not used as a direct-effect denominator on this page | Product company identified; full funding and author COI unverified | Primary vibration perception threshold; secondary NTSS-6, not mean NRS | Favorable secondary NTSS-6 result not attributable to B6 alone | Not used for direct grading of the fixed endpoint: L-methylfolate calcium + methylcobalamin + PLP; no isolation of B6 component. Primary vibration threshold and secondary NTSS-6 are not mean NRS. |
| Dawood et al. 2024 | Prospective open-label randomized study per abstract | Directly eligible pain denominator unverified | Not verified | Metabolic/oxidative stress; not pain NRS | Metabolic results involving B6 and metformin not used as analgesic effects | Not used for direct grading of the fixed endpoint: Newly diagnosed T2DM/metformin oxidative-stress study, not validated pain in painful DSPN. |
| Bae et al. 2013 | Retrospective uncontrolled heterogeneous neuropathic foot-pain report | Directly eligible diabetic pain denominator unverified | Not verified | Heterogeneous foot pain; not an eligible diabetic NRS between-group comparison | Improvement described but not treated as a control-adjusted analgesic effect | Not used for direct grading of the fixed endpoint: Retrospective uncontrolled heterogeneous peripheral-nerve foot pain; no eligible diabetic-specific placebo NRS contrast verified. |
| NCT04689971 vitamin-combination registration | Registry indexing only; latest status and results unverified | Not verified | Not verified | B1/B6/B12 combination registration; not B6 alone | Excluded for combination scope, without claiming that a B6-alone result was reported as absent | Not used for direct grading of the fixed endpoint: B1+B6+B12 add-on, not B6-alone; actual results/status not verified. |
Receipt — 15 References
Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: none
Cite this verdict
[Chamgap] Does pyridoxine hydrochloride alone lower pain NRS in painful diabetic polyneuropathy? — Evidence Grade ?. 15 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/pyridoxine-hydrochloride-diabetic-neuropathy-pain-nrs/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.